JNJ-74856665

DRUG3 trials

Sponsors

Janssen-Cilag International NV, Janssen Research & Development, LLC

Conditions

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMyelodysplastic SyndromesNeoplasmsNon-Hodgkin lymphoma and chronic lymphocytic leukemia Cancer

Phase 1

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CompletedNCT04609826

Janssen Research & Development, LLCAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes

Start: 2020-11-26End: 2025-08-25Updated: 2025-10-01

A rollover study for continued study treatment and ongoing safety monitoring

RecruitingISRCTN87946208

Janssen-Cilag International NVNon-Hodgkin lymphoma and chronic lymphocytic leukemia Cancer

Start: 2024-12-31Target: 77Updated: 2025-03-31

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Enrolling by invitationNCT06788509

Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin +4

Start: 2024-12-30End: 2028-10-30Target: 120Updated: 2026-05-08